1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc.

9606.HK
Duality Biotherapeutics, Inc.HK flagHong Kong Stock Exchange
200.20
HKD
-7.40
- -
18.11BMarket Cap
Duality Biotherapeutics, Inc.
9606.HK
(Hong Kong Stock Exchange)

Recent

price

200.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
FRC
0.02
21.48
23.34
- -
Revenue per Share
-4.65
-4.3
-12.63
- -
Basic EPS, GAAP
-3.87
9.38
3.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
-9.05
-13.9
-26.99
- -
Book Value per Share
-9.86
-14.16
-24.86
- -
Tangible Book Value per Share
83
83
83
- -
Basic Weighted Avg Shares
2
1,787
1,941
1,852
Sales/Revenue/Turnover
-23,107.31
41.45
-10.48
-24.57
Operating Margin (%)
2
5
8
12
Depreciation Expense
-387
-358
-1,050
-2,595
Net Income, GAAP
- -
- -
- -
- -
Effective Tax Rate (%)
-24,193.12
-20.01
-54.11
-140.13
Profit Margin (%)
-826
-1,227
-1,962
2,782
Working Capital
2
2
2
4
LT Debt
-769
-1,124
-2,022
2,427
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-220.02%
Free Cash Flow
- -
- -
-28.96%
Net Income, GAAP
- -
- -
147.02%
Sales/Revenue/Turnover
- -
- -
-4.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
111
- -
- -
- -
1,787
2024
462
479
- -
- -
1,941
2025
- -
- -
- -
- -
1,852

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-4.3
2024
- -
- -
- -
- -
-12.63
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Galapagos N.V. (GLPGF)
ARIAD Pharmaceuticals, Inc. (ARIA)
Hualan Biological Engineering Inc. (002007.SZ)
DBV Technologies S.A. (DBV.PA)
AdAlta Limited (1AD.AX)
Longevity Health Holdings Inc. (XAGEW)
Business
Duality Biotherapeutics Inc. functions as a biotechnology firm in the clinical development phase. It is dedicated to the creation of advanced antibody-drug conjugates, including bispecific and immune-modulating varieties, targeting both oncological and autoimmune conditions. The company originated in 2019 and maintains its principal offices in Shanghai, China. Duality Biotherapeutics leverages proprietary platforms like DITAC to advance a robust pipeline of over a dozen therapeutic candidates. Its portfolio includes lead candidates such as DB-1303 for HER2-expressing cancers, DB-1305 for solid tumors, DB-1310 for lung cancer, DB-1311 for various solid tumors, and DB-2304 for autoimmune diseases like lupus, many of which have received Fast Track designation. The company has established significant global collaborations with pharmaceutical leaders, including BioNTech, GSK, and Avenzo Therapeutics, for the development and commercialization of its innovative treatments across international markets. Duality Biotherapeutics listed on the Hong Kong Stock Exchange in 2025, furthering its commitment to bringing novel therapies to patients worldwide.